Goal of work: We compared the efficacy of ceftriaxone (CA regimen) and piperacillin-tazobactam (PTA regimen) in association with amikacin in the treatment of febrile episodes in severely neutropenic hematological patients. Patients and methods: A total of 252 febrile episodes in 224 patients were randomized. Main results: The CA regimen was effective in 62/122 evaluable episodes (50.8%), and the PTA regimen was effective in 64/121 (52.9%; P > 0.2). Median time to failure was 4 and 5 ays (P > 0.1). Further infections developed in 21/122 episodes (17.2%) with the CA regimen and in 12/121 (9.9%) with the PTA regimen (P=0.06). The overall mortality at the end of the febrile episode was 11/243 (4.5%); seven deaths were considered to be related to infection. Conclusions: Patients treated with piperacillin-tazobactam and amikacin tended to become afebrile sooner and to suffer a lower rate of further infections, even though our data did not show any statistically significant differences between the two groups.

Rossini, F., Terruzzi, E., Verga, L., Larocca, A., Marinoni, S., Miccolis, I., et al. (2005). A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. SUPPORTIVE CARE IN CANCER, 13(6), 387-392 [10.1007/s00520-004-0753-8].

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia

MARINONI, SARA;POGLIANI, ENRICO MARIA
2005

Abstract

Goal of work: We compared the efficacy of ceftriaxone (CA regimen) and piperacillin-tazobactam (PTA regimen) in association with amikacin in the treatment of febrile episodes in severely neutropenic hematological patients. Patients and methods: A total of 252 febrile episodes in 224 patients were randomized. Main results: The CA regimen was effective in 62/122 evaluable episodes (50.8%), and the PTA regimen was effective in 64/121 (52.9%; P > 0.2). Median time to failure was 4 and 5 ays (P > 0.1). Further infections developed in 21/122 episodes (17.2%) with the CA regimen and in 12/121 (9.9%) with the PTA regimen (P=0.06). The overall mortality at the end of the febrile episode was 11/243 (4.5%); seven deaths were considered to be related to infection. Conclusions: Patients treated with piperacillin-tazobactam and amikacin tended to become afebrile sooner and to suffer a lower rate of further infections, even though our data did not show any statistically significant differences between the two groups.
Articolo in rivista - Articolo scientifico
immunocompromised host; piperacillin-tazobactam; ceftriaxone; amikacin; antibiotic therapy
English
2005
13
6
387
392
none
Rossini, F., Terruzzi, E., Verga, L., Larocca, A., Marinoni, S., Miccolis, I., et al. (2005). A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. SUPPORTIVE CARE IN CANCER, 13(6), 387-392 [10.1007/s00520-004-0753-8].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/15065
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
Social impact